Skip to main content
The Markets by Proactive
Go to Proactive Australia

Medical technology & services

CardieX completes $2.5 million placement from new strategic investors

The company and lead manager Sixty Two Capital Pty Ltd looked to new investors with a long-term view and alignment with the company’s strategic focus towards the development of its new product range.

CardieX Ltd (ASX:CDX) has completed a $2.5 million placement at 3 cents per share with a 1 for 5 free attaching listed option (CDXO) at an exercise price of 5 cents, resulting in the issue of around 83 million new shares and 16.6 million new listed options.

The company received strong demand from new sophisticated, wholesale and existing investors.

In offering the placement to new investors, the company and Sixty Two Capital looked to identify groups with a long-term view and alignment on the company’s strategic focus towards the development of its new product range.

Chief executive officer Craig Cooper said: “We are pleased with the significant interest we received from sophisticated, and wholesale investors through this placement, particularly during the current uncertain period, and that the placement has been well supported largely by new shareholders who have a shared vision for the strategic focus and unique opportunity of CardieX.

“It is pleasing to see this vision shared by new shareholders with a longer-term view of CardieX’s value proposition.

“We now have a stronger share register with a wider representation, and a stronger balance sheet to take us forward through this period of scaling up our previously announced plans to move forward with our new product development program.”

Funding product development

The company believes the offer price, which represents a discount of less than 4% to the last traded price of CardieX prior to the company’s application for a trading halt, is competitively priced for existing shareholders and the new incoming placement participants.

When combined with a current cash balance of around $2.4 million, the company is well-funded to achieve its current milestones related to wearable technologies and new medical device developments.

Placement funds will be applied towards working capital for the company’s existing operations and supporting the acceleration of the company’s product development program.

Indicative timetable

The settlement and issue of placement shares is scheduled for Friday, July 31, 2020, with the ASX quotation of placement shares expected on Monday, August 3, 2020.

Dispatch of shareholder statements for placement participants will occur on Monday, August 3, 2020.

Extraordinary General Meeting

In addition to the placement, the CardieX has announced its intention to shortly hold an Extraordinary General Meeting.

The company will shortly advise shareholders of the notice and timing of the meeting, which will seek shareholder approval to ratify the placement of C2 Ventures Pty Ltd (related entity of chairman Niall Cairn’s and CEO Craig Cooper) of $500,000 in additional capital (previously announced in December 2019).